Brian Rabinovich

Drug Discovery Laboratory (Norway) — Norway

Immunology and Microbiology · Life Sciences

31h-index4.5kcitations164works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(64), CAR-T cell therapy research(50), Cancer Immunotherapy and Biomarkers(32), Virus-based gene therapy research(27), CRISPR and Genetic Engineering(26)

Publications162 total

Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activity
Frontiers in Immunology·2025Open Access
Computational Prediction of Single-Domain Immunoglobulin Aggregation Propensities Facilitates Discovery and Humanization of Recombinant Nanobodies
Antibodies·2025· 2 citedOpen Access
958 Targeting functionally specific IL-18 (F-18) to PD-1: a next generation checkpoint inhibitor with enhanced anti-tumor activity
Regular and Young Investigator Award Abstracts·2024Open Access
959 Next generation cell engagers that effectively target, redirect, expand and oppose functional exhaustion of small lymphocyte populations that decouple on-target-off- tumor toxicity
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
Abstract 4075: Targeting attenuated IL-18 to PD-1: A next generation checkpoint inhibitor with enhanced anti-tumor activity
Cancer Research·2024
Using protein geometry to optimize cytotoxicity and the cytokine window of a ROR1 specific T cell engager
Frontiers in Immunology·2024· 9 citedOpen Access
Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
mAbs·2024· 18 citedOpen Access
Figure S1 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
Figure S6 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
Figure S3 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
Figure S5 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
Figure S4 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
Figure S11 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
Figure S4 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
Figure S7 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
Supplementary Tables from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
Data from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
Figure S3 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
Figure S12 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
Figure S1 from M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation
2024Open Access
page 1 of 9Next →

Frequent Co-authors

Laurence J.N. Cooper(11), Richard G. Miller(8), Simon Olivares(7), Richard E. Champlin(7), Juri G. Gelovani(7), Dean A. Lee(6), Willem W. Overwijk(5), Harjeet Singh(5), Amer Najjar(5), Tiejuan Mi(5), Sourindra N. Maiti(5), Helen Huls(5), Patrick Hwu(5), David Cosman(5), Mian M. Alauddin(5), Chengwen Liu(4), Yanyan Lou(4), Kirsten C. Switzer(4), Jennifer Li(4), Rose Hurren(4)